Studies have shown that SERPINE1 inhibitors exhibit anti-leukemia effects in mice model of CML, and the combination of SERPINE1 inhibitor and TKI achieves a higher molecular response rate in CML patients than monotherapy with TKIs [47, 48]. The gene discussed is SERPINE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.